In patients with acute heart failure (AHF), low-dose carperitide use was found to be significantly linked with lower cardiovascular and all-cause mortality within 1 year post-admission.

• Researchers assessed the data of COOPERATE-HF-J (the Consortium for Pooled Data Analysis regarding Hospitalized Patients with Heart Failure in Japan), integrating two cohorts (NARA-HF and REALITY-AHF), which comprised 2,435 patients with acute decompensated heart failure.

• Participants were categorized as no carperitide (NO-ANP, n = 1,098); very low-dose carperitide (VLD-ANP, <0.02 μg/kg/min, n = 593); and low-dose carperitide groups (LD-ANP, ≥0.02 μg/kg/min, n = 744).

• In the VLD-ANP and LD-ANP groups, median carperitide doses were 0.013 and 0.025 μg/kg/min, respectively.

• In the Kaplan–Meier analysis, the LD-ANP group exhibited significantly lower cardiovascular as well as all-cause mortalities in comparison to the NO-ANP and VLD-ANP groups.

• In the multivariable Cox regression analysis, LD-ANP was shown to be significantly linked with lower cardiovascular and all-cause mortality within 1 year post-admission, even post-adjusting other covariates (hazard ratio: 0.696 and 0.791, respectively).